Price Alert

Radiopharm Theranostics L... (RADX)

NASDAQ: RADX · Real-Time Price · USD

6.20

0.14 (2.31%)

At close: Oct 03, 2025, 3:55 PM

Radiopharm Theranostics Statistics

Share Statistics

Radiopharm Theranostics has n/a shares outstanding. The number of shares has increased by 4867.42% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	4867.42%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	819.52K
Failed to Deliver (FTD) Shares	33
FTD / Avg. Volume	0.11%

Short Selling Information

The latest short interest is 44.07K, so 0% of the outstanding shares have been sold short.

Short Interest	44.07K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.72

Valuation Ratios

The PE ratio is -1.28 and the forward PE ratio is -1. Radiopharm Theranostics's PEG ratio is 0.01.

PE Ratio	-1.28
Forward PE	-1
PS Ratio	13.46
Forward PS	2.6
PB Ratio	1.09
P/FCF Ratio	-1.33
PEG Ratio	0.01

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Radiopharm Theranostics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.67, with a Debt / Equity ratio of 0.

Current Ratio	2.67
Quick Ratio	2.67
Debt / Equity	0
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-584.59

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	undefined
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	103.29K
Effective Tax Rate	-0.27%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.91, so Radiopharm Theranostics's price volatility has been higher than the market average.

Beta	0.91
52-Week Price Change	n/a
50-Day Moving Average	5.61
200-Day Moving Average	4.96
Relative Strength Index (RSI)	55.04
Average Volume (20 Days)	29,955

Income Statement

In the last 12 months, Radiopharm Theranostics had revenue of 3.63M and earned -38.34M in profits. Earnings per share was -5.28.

Revenue	3.63M
Gross Profit	39.28K
Operating Income	-38.17M
Net Income	-38.34M
EBITDA	-38.17M
EBIT	-38.17M
Earnings Per Share (EPS)	-5.28

Full Income Statement

Balance Sheet

The company has 29.12M in cash and 0 in debt, giving a net cash position of 29.12M.

Cash & Cash Equivalents	29.12M
Total Debt	n/a
Net Cash	n/a
Retained Earnings	-145.73M
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -36.65M and capital expenditures 0, giving a free cash flow of -36.65M.

Operating Cash Flow	-36.65M
Capital Expenditures	n/a
Free Cash Flow	-36.65M
FCF Per Share	-5.28

Full Cash Flow Statement

Margins

Gross margin is 1.08%, with operating and profit margins of -1050.63% and -1055.27%.

Gross Margin	1.08%
Operating Margin	-1050.63%
Pretax Margin	-1052.43%
Profit Margin	-1055.27%
EBITDA Margin	-1050.43%
EBIT Margin	-1050.63%
FCF Margin	-1008.57%

Dividends & Yields

RADX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RADX is $15, which is 141.9% higher than the current price. The consensus rating is "Buy".

Price Target	$15
Price Target Difference	141.9%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a